JP2023519246A5 - - Google Patents

Info

Publication number
JP2023519246A5
JP2023519246A5 JP2022557767A JP2022557767A JP2023519246A5 JP 2023519246 A5 JP2023519246 A5 JP 2023519246A5 JP 2022557767 A JP2022557767 A JP 2022557767A JP 2022557767 A JP2022557767 A JP 2022557767A JP 2023519246 A5 JP2023519246 A5 JP 2023519246A5
Authority
JP
Japan
Prior art keywords
rnai drug
rnai
sense strand
drug according
nucleotide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022557767A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023519246A (ja
JP7830340B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/024299 external-priority patent/WO2021195467A2/en
Publication of JP2023519246A publication Critical patent/JP2023519246A/ja
Publication of JP2023519246A5 publication Critical patent/JP2023519246A5/ja
Priority to JP2025168554A priority Critical patent/JP2026010008A/ja
Application granted granted Critical
Publication of JP7830340B2 publication Critical patent/JP7830340B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022557767A 2020-03-26 2021-03-26 PNPLA3の発現を阻害するためのRNAi薬、その医薬組成物、及び使用方法 Active JP7830340B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025168554A JP2026010008A (ja) 2020-03-26 2025-10-06 PNPLA3の発現を阻害するためのRNAi薬、その医薬組成物、及び使用方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063000137P 2020-03-26 2020-03-26
US63/000,137 2020-03-26
PCT/US2021/024299 WO2021195467A2 (en) 2020-03-26 2021-03-26 RNAi AGENTS FOR INHIBITING EXPRESSION OF PNPLA3, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USE

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025168554A Division JP2026010008A (ja) 2020-03-26 2025-10-06 PNPLA3の発現を阻害するためのRNAi薬、その医薬組成物、及び使用方法

Publications (3)

Publication Number Publication Date
JP2023519246A JP2023519246A (ja) 2023-05-10
JP2023519246A5 true JP2023519246A5 (cg-RX-API-DMAC7.html) 2024-04-03
JP7830340B2 JP7830340B2 (ja) 2026-03-16

Family

ID=75540055

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022557767A Active JP7830340B2 (ja) 2020-03-26 2021-03-26 PNPLA3の発現を阻害するためのRNAi薬、その医薬組成物、及び使用方法
JP2025168554A Pending JP2026010008A (ja) 2020-03-26 2025-10-06 PNPLA3の発現を阻害するためのRNAi薬、その医薬組成物、及び使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025168554A Pending JP2026010008A (ja) 2020-03-26 2025-10-06 PNPLA3の発現を阻害するためのRNAi薬、その医薬組成物、及び使用方法

Country Status (21)

Country Link
US (2) US12054718B2 (cg-RX-API-DMAC7.html)
EP (1) EP4125932A2 (cg-RX-API-DMAC7.html)
JP (2) JP7830340B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220158011A (cg-RX-API-DMAC7.html)
CN (2) CN120699970A (cg-RX-API-DMAC7.html)
AR (1) AR121672A1 (cg-RX-API-DMAC7.html)
AU (2) AU2021242321B2 (cg-RX-API-DMAC7.html)
BR (1) BR112022019241A2 (cg-RX-API-DMAC7.html)
CA (1) CA3176418A1 (cg-RX-API-DMAC7.html)
CL (2) CL2022002580A1 (cg-RX-API-DMAC7.html)
CO (1) CO2022013746A2 (cg-RX-API-DMAC7.html)
CR (1) CR20220532A (cg-RX-API-DMAC7.html)
DO (1) DOP2022000204A (cg-RX-API-DMAC7.html)
EC (1) ECSP22075322A (cg-RX-API-DMAC7.html)
IL (1) IL296718A (cg-RX-API-DMAC7.html)
JO (1) JOP20220232A1 (cg-RX-API-DMAC7.html)
MX (1) MX2022011907A (cg-RX-API-DMAC7.html)
PE (1) PE20230345A1 (cg-RX-API-DMAC7.html)
TW (1) TWI924663B (cg-RX-API-DMAC7.html)
UY (1) UY39138A (cg-RX-API-DMAC7.html)
WO (1) WO2021195467A2 (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20170056B1 (ar) * 2016-09-02 2021-08-17 Arrowhead Pharmaceuticals Inc مركبات ترابطية مستهدفة
CA3065523A1 (en) 2017-06-02 2018-12-06 Wave Life Sciences Ltd. Oligonucleotide compositions and methods of use thereof
US11603532B2 (en) 2017-06-02 2023-03-14 Wave Life Sciences Ltd. Oligonucleotide compositions and methods of use thereof
JP2021521140A (ja) 2018-04-12 2021-08-26 ウェイブ ライフ サイエンシズ リミテッドWave Life Sciences Ltd. オリゴヌクレオチド組成物及びその使用方法
CA3098624A1 (en) 2018-05-11 2019-11-14 Wave Life Sciences Ltd. Oligonucleotide compositions and methods of use thereof
WO2022256395A1 (en) * 2021-06-02 2022-12-08 Alnylam Pharmaceuticals, Inc. Patatin-like phospholipase domain containing 3 (pnpla3) irna compositions and methods of use thereof
CN119789859A (zh) * 2022-04-08 2025-04-08 箭头药业股份有限公司 非酒精性脂肪肝病的治疗
WO2025223315A1 (zh) * 2024-04-25 2025-10-30 苏州时安生物技术有限公司 一种用于肝脏特异性递送的多靶标双链rna偶联物及药物组合物
WO2026130520A1 (zh) * 2024-12-20 2026-06-25 正大天晴药业集团股份有限公司 靶向pnpla3的双链核糖核酸

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
NL9201440A (nl) 1992-08-11 1994-03-01 Univ Leiden Triantennaire clusterglycosiden, hun bereiding en toepassing.
US5998203A (en) 1996-04-16 1999-12-07 Ribozyme Pharmaceuticals, Inc. Enzymatic nucleic acids containing 5'-and/or 3'-cap structures
WO2000053722A2 (en) 1999-03-10 2000-09-14 Phogen Limited Delivery of nucleic acids and proteins to cells
CN101500548A (zh) 2006-08-18 2009-08-05 弗·哈夫曼-拉罗切有限公司 用于体内递送多核苷酸的多缀合物
PH12012501596A1 (en) 2010-02-24 2017-02-03 Arrowhead Res Corporation Compositions for targeted delivery of sirna
US8501930B2 (en) 2010-12-17 2013-08-06 Arrowhead Madison Inc. Peptide-based in vivo siRNA delivery system
CA2842039A1 (en) 2011-08-26 2013-03-07 Arrowhead Research Corporation Poly(vinyl ester) polymers for in vivo nucleic acid delivery
MX2014001965A (es) 2012-04-18 2014-03-31 Arrowhead Res Corp Polimeros de poli(acrilato) para suministro de acido nucleico in vivo.
JP2018510621A (ja) 2015-02-13 2018-04-19 アルナイラム ファーマシューティカルズ, インコーポレイテッドAlnylam Pharmaceuticals, Inc. パタチン様ホスホリパーゼドメイン含有3(PNPLA3)iRNA組成物およびその使用方法
JOP20160211B1 (ar) * 2015-10-01 2021-08-17 Arrowhead Pharmaceuticals Inc تراكيب وأساليب لتثبيط تعبير جيني للـ lpa
JOP20170057B1 (ar) 2016-03-07 2022-03-14 Arrowhead Pharmaceuticals Inc مركبات ترابطية مستهدفة كمركبات علاجية
US10036024B2 (en) * 2016-06-03 2018-07-31 Purdue Research Foundation siRNA compositions that specifically downregulate expression of a variant of the PNPLA3 gene and methods of use thereof for treating a chronic liver disease or alcoholic liver disease (ALD)
JOP20170056B1 (ar) * 2016-09-02 2021-08-17 Arrowhead Pharmaceuticals Inc مركبات ترابطية مستهدفة
MX2020001912A (es) * 2017-09-14 2020-03-24 Arrowhead Pharmaceuticals Inc Agentes de iarn y composiciones para inhibir la expresion de la angiopoyetina tipo 3 (angptl3) y metodos de uso.
AR113490A1 (es) * 2017-12-12 2020-05-06 Amgen Inc CONSTRUCCIONES DE ARNi PARA INHIBIR LA EXPRESIÓN DE PNPLA3 Y MÉTODOS DE USO DE LAS MISMAS
CN115176007A (zh) * 2019-12-16 2022-10-11 阿尔尼拉姆医药品有限公司 含类PATATIN磷脂酶结构域3(PNPLA3)iRNA组合物及其使用方法

Similar Documents

Publication Publication Date Title
JP2020533334A5 (cg-RX-API-DMAC7.html)
CN113164509B (zh) 用于抑制17β-HSD 13型(HSD17B13)表达的RNAi试剂、其组合物和使用方法
JP2022501040A5 (cg-RX-API-DMAC7.html)
JP6924744B2 (ja) B型肝炎ウイルスに対する組成物および薬剤ならびにその使用
TWI881004B (zh) 用於治療hbv之靶向hbv的治療性寡核苷酸及tlr7促效劑之醫藥組合
JP2023536974A5 (cg-RX-API-DMAC7.html)
KR20200097751A (ko) 근위축증 및 근긴장성 이영양증을 치료하는 조성물 및 방법
JP2020534268A5 (cg-RX-API-DMAC7.html)
JP2018529732A5 (cg-RX-API-DMAC7.html)
JP2019513384A5 (cg-RX-API-DMAC7.html)
JP2023536999A (ja) B型肝炎患者のオリゴヌクレオチド処置
US20240425859A1 (en) Pharmaceutical combinations for treatment of hbv
JP2024539193A5 (cg-RX-API-DMAC7.html)
JP2022517742A5 (cg-RX-API-DMAC7.html)
JP2024544532A5 (cg-RX-API-DMAC7.html)
IL323704A (en) Compounds and methods for reducing pln expression
US20230123601A1 (en) Pharmaceutical combination of antiviral agents targeting hbv and/or an immune modulator for treatment of hbv
JP2023541170A (ja) Z-aatタンパク質のレベルを低下させる方法
JP2024026903A (ja) siRNA及び医薬組成物並びに予防及び/又は治療剤
WO2021107143A1 (ja) アンチセンス核酸の毒性を軽減する方法
HK40110728A (en) Pharmaceutical combinations for treatment of hbv
CN121003688A (zh) 一种dsRNA与干扰素的联合治疗
CN120829899A (zh) 用于抑制NR1H3基因表达的RNAi剂及其制备方法和用途
CN117645995A (zh) 抑制去唾液酸糖蛋白受体基因表达的siRNA、其缀合物和药物组合物及用途
TH2001001206A (th) RNAi เอเจนท์และองค์ประกอบสำหรับการยับยั้งการแสดงออกของอะโปลิโพโปรตีน C-II (APOC3)